EPHA2 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain EPHA2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

EPHA2 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].